Paradigm has announced a partnership with Bristol Myers Squibb to develop a new end-to-end clinical trial operating model that spans design, recruitment, and data collection. Beginning with oncology and eventually expanding to other therapeutic...
Novartis announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) intravenous (IV) formulation for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non...
Zhifei, China's largest vaccines producer, will pay British drugmaker GSK 2.5 billion pounds ($3.05 billion pounds) for exclusive distribution rights to GSK's shingles vaccine in the world's No.2 pharmaceuticals market. The agreement is part of a...
The FDA has approved Biomea's IND application to study BMF-219 in adults with type 1 diabetes, according to Biomea Fusion, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to...
Bristol Myers Squibb, a US pharmaceutical corporation, announced a $4.8 billion deal to purchase cancer drugmaker Mirati Therapeutics. Bristol Myers Squibb will pay $58 per share in cash "for a total equity value of $4.8 billion," according to the...
The US Food and Drug Administration (FDA) has approved EntroGen's CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix (panitumumab), a colorectal cancer targeted therapy. This historic premarket approval (PMA) represents a...
India and Taiwan have formed a new partnership to develop and promote breakthrough health-tech solutions. The International Trade Administration, Government of Taiwan, and the Commerce Development Research Institute (CDRI), as the Taiwan...
Deuruxolitinib is an experimental medication for the treatment of moderate to severe alopecia areata, and Sun Pharmaceutical Industries Ltd. has reported that the United States Food and Drug Administration (USFDA) has approved its new drug...
Sai Life Sciences, the fastest-growing contract research, development, and manufacturing company in India, has chosen Dassault Systèmes' solutions to boost productivity, improve data quality, and promote collaboration in its research and...
Transcenta Holding Limited, a clinical stage biopharmaceutical company, announces that the FDA has approved the TranStar 301 global phase III pivotal trial of Osemitamab (TST001) in combination with Nivolumab and chemotherapy as first-line...
, CDSCO.jpg)
